Immunohistochemical analysis of peritoneal mesothelioma and primary and secondary serous carcinoma of the peritoneum - Ant bodies to estrogen and progesterone receptors are useful

被引:59
作者
Barnetson, RJ
Burnett, RA
Downie, I
Harper, CM
Roberts, F
机构
[1] Univ Glasgow, Western Infirm, Dept Pathol, Glasgow G11 6NT, Lanark, Scotland
[2] Glasgow Royal Infirm, Glasgow G4 0SF, Lanark, Scotland
[3] So Gen Hosp, Glasgow G51 4TF, Lanark, Scotland
关键词
peritoneal mesothelioma; primary peritoneal carcinoma; metastatic ovarian carcinoma; estrogen receptor; progesterone receptor;
D O I
10.1309/8FCHQ3VPBWM7B5X9
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The role of immunohistochemical markers in distinguishing peritoneal mesothelioma from primary or metastatic serous papillary carcinoma of the peritoneum was evaluated. We immunostained 20 peritoneal mesotheliomas (front 14 men and 6 women), 14 primary peritoneal carcinomas, and 14 metastatic serous ovarian carcinomas with a panel of 16 antibodies. Positive staining for calretinin was identified in 17 (85%) of 20 mesotheliomas, but all carcinomas were negative. Positive staining for Ber-EP4 was identified in 27 (96%) of 28 carcinomas and in 2 (10%) of 20 mesotheliomas. Estrogen receptors were positive in 26 (93%) of 28 carcinomas, and progesterone receptors were positive in 8 (29%) of 28 carcinomas. All mesotheliomas were negative for estrogen and progesterone receptors. The other antibodies evaluated were insufficiently sensitive and/or specific to be diagnostically useful. In conjunction with calretinin and Ber-EP4, estrogen and progesterone receptors are useful discriminators, markers for distinguishing peritoneal mesothelioma from primary or metastatic serous carcinoma.
引用
收藏
页码:67 / 76
页数:10
相关论文
共 59 条
[1]   Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies [J].
Abutaily, AS ;
Addis, BJ ;
Roche, WR .
JOURNAL OF CLINICAL PATHOLOGY, 2002, 55 (09) :662-668
[2]   WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma [J].
Al-Hussaini, M ;
Stockman, A ;
Foster, H ;
McCluggage, WG .
HISTOPATHOLOGY, 2004, 44 (02) :109-115
[3]   CD44H expression in reactive mesothelium, pleural mesothelioma and pulmonary adenocarcinoma [J].
Attanoos, RL ;
Webb, R ;
Gibbs, AR .
HISTOPATHOLOGY, 1997, 30 (03) :260-263
[4]   Malignant epithelioid mesothelioma: anti-mesothelial marker expression correlates with histological pattern [J].
Attanoos, RL ;
Webb, R ;
Dojcinov, SD ;
Gibbs, AR .
HISTOPATHOLOGY, 2001, 39 (06) :584-588
[5]   Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum [J].
Attanoos, RL ;
Webb, R ;
Dojcinov, SD ;
Gibbs, AR .
HISTOPATHOLOGY, 2002, 40 (03) :237-244
[6]   Pathology of malignant mesothelioma [J].
Attanoos, RL ;
Gibbs, AR .
HISTOPATHOLOGY, 1997, 30 (05) :403-418
[7]  
BOLLINGER DJ, 1989, HISTOPATHOLOGY, V40, P237
[8]   The epidemiology of mesothelioma [J].
Britton, M .
SEMINARS IN ONCOLOGY, 2002, 29 (01) :18-25
[9]   Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma - A study with logistic regression analysis [J].
Carella, R ;
Deleonardi, G ;
D'Errico, A ;
Salerno, A ;
Egarter-Vigl, E ;
Seebacher, C ;
Donazzan, G ;
Grigioni, WF .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2001, 25 (01) :43-50
[10]   Expression of cytokeratins 7 and 20 in ovarian neoplasia [J].
Cathro, HP ;
Stoler, MH .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2002, 117 (06) :944-951